"I remember all too well my own journey with Langerhans cell histiocytosis in 1992; the limited information that existed and the limited treatment options. I remember so clearly how much had changed by 2017 when I joined the Board of Trustees; it was evident the impact the discovery of genetic mutations had made on the knowledge, understanding, and treatment options for histiocytosis. Five years later, I am amazed at how the conversation continues to evolve, whereas we are exploring harmonization, collaboration, pursuing natural history studies, seeing positive outcomes, and have over 3 FDA approved therapies for histiocytosis."
-Deanna Fournier, Executive Director
Hover over the photos to read what Histiocytosis Association programs benefited these patients and families.